JNJ vs MCD: How Johnson & Johnson and McDonald's Compare (2026)

Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. JNJ and MCD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined JNJ and MCD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Johnson & Johnson is one of the world's largest healthcare companies, now focused on two core areas after spinning off its consumer-health business (Kenvue). Its Innovative Medicine segment develops and sells branded prescription drugs across oncology, immunology, neuroscience, cardiovascular, and other areas, with major franchises that drive much of its profit. Its MedTech segment makes medical devices and surgical equipment for cardiovascular intervention, orthopedics, surgery, and vision care. J&J makes money by researching, manufacturing, and selling patented pharmaceuticals and devices to hospitals, physicians, pharmacies, and patients worldwide, supported by one of the largest research and development budgets in healthcare. The company is known for its diversification, financial strength, AAA-class balance sheet, and a multi-decade record of raising its dividend, making it a classic defensive blue chip. Founded in 1886 and headquartered in New Brunswick, New Jersey, J&J is a broadly held, large-cap healthcare company valued for stability, income, and a deep drug and device pipeline.

Full JNJ guide

McDonald's is the world's largest restaurant company by system-wide sales, operating and franchising roughly 43,000 quick-service restaurants across more than 100 countries. The menu centers on burgers, fries, chicken, breakfast, and beverages. The business is fundamentally a franchising and real estate model: about 95% of McDonald's locations are owned and operated by independent franchisees, and the company collects rent and royalties on system sales rather than running most restaurants directly. This asset-light structure produces high margins and steady, recurring cash flow. McDonald's also owns much of the real estate beneath its restaurants, making property income a meaningful and durable revenue stream. Growth levers include digital ordering, delivery partnerships, the loyalty program, value menus, and the CosMc's beverage concept. Founded in 1955 and headquartered in Chicago, McDonald's is one of the most recognizable consumer brands in the world and a long-standing dividend grower.

Full MCD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• JNJ drivers: Innovative Medicine pipeline; MedTech innovation and recovery.
• MCD drivers: Franchise and real estate model; Digital, delivery, and loyalty.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: J&J faces patent expirations on key drugs, including the eventual loss of exclusivity for major franchises, which requires the pipeline to continually replace lost revenue. For MCD, mcDonald's faces traffic pressure when value-seeking consumers cut discretionary spending or perceive fast food as no longer cheap after years of price increases.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick JNJ if you believe its drivers more; MCD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the JNJ and MCD guides.

JNJ. J&J trades at a valuation typical of a large, defensive healthcare blue chip: a moderate multiple reflecting steady low-to-mid single-digit growth, high margins, and very strong cash generation, plus a discount for litigation and patent-cliff overhangs. The market values its diversification, balance-sheet strength, and long dividend record, pricing it as a stable income-and-quality holding rather than a growth stock.

MCD. McDonald's trades at a premium to the broad market, reflecting the durability of its franchise and real estate model, its global scale, and a multi-decade dividend-growth record. The valuation embeds steady mid-single-digit system-sales growth and reliable cash generation rather than rapid expansion. The premium has historically compressed only during periods of weak same-store traffic.

Headline figures (approximate, early 2026): JNJ shows revenue (ttm) ~$90 billion, operating margin ~25%, net income (ttm) ~$15 billion, p/e (ttm) ~16x; MCD shows revenue (ttm) ~$26 billion (company revenue; system-wide sales are far larger at ~$130 billion+), operating margin ~45% (high, due to the franchise and royalty model), net income (ttm) ~$8.5 billion, eps (ttm) ~$11.80.

JNJ and MCD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined JNJ and MCD exposure against your real portfolio. It is not an investment adviser.